Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.69 |
| ▸ | PAM | P19021 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.53 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.53 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | PRKCA | P17252 | 1/20 | 0.51 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.51 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2181324 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL2217057 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL2182828 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL2183449 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL2145671 | 1.00 | DGKA (0.69) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL6893576 | 0.98 | DGKA (0.65) | DGKAPAMTSHRMAPTLMNA | |
| Chloroform SCHEMBL8307778 | 0.92 | DGKA (0.60) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL8680864 | 0.91 | — | — | |
| Chloroform SCHEMBL8310130 | 0.90 | DGKA (0.57) | DGKAPAMTSHRMAPTLMNA | |
| SCHEMBL19193404 | 0.89 | DGKA (0.61) | DGKAMAPTLMNADUSP3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122070276-A | Prodrugs of xanomeline, prodrugs of trospium chloride and methods of using the same | 人类生物科学股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4705289-A1 | PRODRUGS OF XANOMELINE, PRODRUGS OF TROSPIUM AND METHODS OF USE THEREOF | Terran Biosciences Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250066376-A1 | OPIOID RECEPTOR ANTAGONIST PRODRUGS | NIRSUM LABORATORIES INC (US) | 2025-02-27 | — | — | US | disclosed |
| WO-2024226691-A1 | PRODRUGS OF XANOMELINE, PRODRUGS OF TROSPIUM AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| EP-2445343-B1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES PHARMA IRELAND LTD (IE) | 2021-08-04 | — | — | EP | disclosed |
| US-10723728-B2 | Prodrugs of Nh-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-07-28 | — | — | US | disclosed |
| US-10428058-B2 | Prodrugs of NH-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2019-10-01 | — | — | US | disclosed |
| US-20190284181-A9 | PRODRUGS OF NH-ACIDIC COMPOUNDS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-09-19 | — | — | US | disclosed |
| US-20190031648-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES PHARMA IRELAND LTD (IE) | 2019-01-31 | — | — | US | disclosed |
| US-10040787-B2 | Prodrugs of NH-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-08-07 | — | — | US | disclosed |
| WO-2011084846-A1 | QUATERNARY AMMONIUM SALT PRODRUGS | ALKERMES, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011084848-A2 | PRODRUGS OF HETERAROMATIC COMPOUNDS | ALKERMES, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011084850-A1 | PRODRUGS FOR THE TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISEASE | ALKERMES, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20110166194-A1 | Asenapine Prodrugs | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110003828-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES, INC. | 2011-01-06 | — | — | US | disclosed |
| US-20110003828-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES, INC. | 2011-01-06 | — | — | US | disclosed |
| US-20110003828-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES, INC. | 2011-01-06 | — | — | US | disclosed |
| WO-2010151711-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES, INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010151711-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES, INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066376-A1 | OPIOID RECEPTOR ANTAGONIST PRODRUGS | OPRL1, OPRM1, OPRD1 | DGKA 3915/4885PAM 68/4885TSHR 209/4885 |
| US-20190031648-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | SI, NAAA, NIT2 | DGKA 4304/4885PAM 74/4885TSHR 3738/4885 |
| US-10040787-B2 | Prodrugs of NH-acidic compounds | SI, NAAA, NIT2 | DGKA 4304/4885PAM 74/4885TSHR 3738/4885 |
| US-20190284181-A9 | PRODRUGS OF NH-ACIDIC COMPOUNDS | SI, NAAA, NIT2 | DGKA 4304/4885PAM 74/4885TSHR 3738/4885 |
| US-20110166194-A1 | Asenapine Prodrugs | GRIN1, SCN1B, GRIN2B | DGKA 2898/4885PAM 1762/4885TSHR 520/4885 |
| US-10428058-B2 | Prodrugs of NH-acidic compounds | SI, NAAA, NIT2 | DGKA 4304/4885PAM 74/4885TSHR 3738/4885 |
| US-20110166156-A1 | Prodrugs for the Treatment of Schizophrenia and Bipolar Disease | SLC1A2, BDNF, MAOB | DGKA 2298/4885PAM 1487/4885TSHR 1502/4885 |
| US-20110003828-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | SI, NAAA, NIT2 | DGKA 4304/4885PAM 74/4885TSHR 3738/4885 |
| US-10723728-B2 | Prodrugs of Nh-acidic compounds | SI, NAAA, NIT2 | DGKA 4304/4885PAM 74/4885TSHR 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.